Insights on the Decline (and Possible Rise) in New Medical, Pharma Filings in Federal Court
Insights April 4, 2018
Rimon’s complex litigator, Dennis Raglin, was quoted in the New York Law Journal on the recent decline of medical device and pharmaceutical litigation filings. He believes these filings ebb and flow due to various factors, including the economy, state tort reform, and how judges rule on motions that impact future cases, as well as whether drug and device companies decide to settle blockbuster litigations earlier or push forward to trial.
Dennis suggested that the recent opioid litigation in Ohio federal court where plaintiffs have alleged products liability theories against drug companies for the sale and spread of these drugs is novel in some respects and, depending on what the judge allows after defense motions, may break new ground and could lead to an increase in filings of similar suits.
Dennis Raglin is a member of Rimon’s Litigation practice where he specializes in defending clients in the areas of products liability, including medical device and pharmaceutical, and in all types of general and complex litigation. He also counsels and defends clients in California’s Proposition 65 right-to-know chemical warnings law and green chemistry regulations in California and nationwide. Mr. Raglin has over twenty years of extensive litigation experience and has tried cases to verdict, including to defense verdict, and has achieved dismissals and summary judgments, as well as favorable settlements in mediation and arbitration, for a diverse group of clients. In his Proposition 65 and green chemistry practice, in addition to defending clients who have received notices of violation or are involved in litigation, Mr. Raglin advises companies large and small before litigation on minimizing their risk and employing best practices to ensure compliance with these often complicated laws. Read more about Dennis here.